A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
DRUG

Etavopivat

400 mg once daily

Trial Locations (18)

10016

NYU Langone Health, New York

10032

Columbia University Irving Medical Center, New York

33136

University of Miami Hospital and Clinics, Miami

33600

Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-1, Pessac

34474

Ocala Oncology, Ocala

55124

Charite Universitätsmedizin Berlin, Mainz

Universitätsklinikum Leipzig, Klinik und Poliklinik, Mainz

92936

Master centre for France, Paris La Défense

08536

Cedars-Sinai Medical Center, Plainsboro

Northwell Health, Plainsboro

Northwestern Memorial Hospital, Plainsboro

The Ohio State University Medical Center, Plainsboro

V6Z 2K5

University of British Columbia - St. Paul's Hospital, Vancouver

06200

Nice University Hospital - Hôpital de l'Archet, Route de Saint-Antoine

Unknown

Hopital Saint Louis, Paris

Universitoetsklinikum Heidelberg, Heidelberg

Universitaetsklinikum Muenster, Münster

Universitoetsklinikum Halle (Saale), Münster

Sponsors
All Listed Sponsors
lead

Forma Therapeutics, Inc.

INDUSTRY

NCT05568225 - A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter